samedan logo
 
 
 
spacer
home > pmps > winter 2017 > watching the east
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Watching the East

The pharmaceutical industry is one of the most competitive sectors in the EU. It is the fifth largest industrial area and accounts for a high percentage of the global pharma market. According to the European Federation of Pharmaceutical Industries and Associations, few other fields can match its contribution to generating a trade surplus, investment in R&D and the creation of skilled employment in Europe.

While a large proportion of pharmaceutical development and manufacturing takes place on the western continent, central and eastern European countries are emerging as an attractive alternative for companies wishing to outsource parts of the supply chain due to factors such as accomplished workforces and competitive pricing.

European Landscape

The pharma sector in Europe has grown exponentially over the past ten years. Businesses have had to overcome a number of challenges, like escalating costs and downward price pressure from governments coupled with the need for faster turnaround times to bring new drugs to market, as well as increased demand for products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Anthony Sheehan joined Saneca Pharma as Chief Executive Officer in 2015. With over 25 years’ experience in the pharma industry, he has worked as Site Managing Director at Stada as well as in various senior roles within the sector. Anthony also has experience in the automotive and engineering fields. He has an MBA from the University of Limerick, Ireland.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement